CSA Medical
CSA Medical is a US private medical device company developing the RejuvenAir System, a bronchoscopic liquid nitrogen spray cryotherapy platform that targets the underlying cause of chronic bronchitis in COPD patients. It serves interventional pulmonologists and major medical centers, holds FDA Breakthrough Designation, has submitted a PMA in January 2026, and is CE Mark commercial in the EU.
- Company typePrivate
- Founded1993
- HeadquartersLutherville Timonium, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CSA Medical does
CSA Medical is a privately held US medical device company developing the RejuvenAir System, a bronchoscopic spray cryotherapy platform designed to treat the underlying cause of chronic bronchitis in patients with COPD. The company's core technology, Metered CryoSpray (MCS), delivers precise doses of -196°C liquid nitrogen through a unique circumferential cryospray catheter and proprietary energy control algorithm that flash-freezes damaged airway cells while preserving the extracellular matrix, enabling a rejuvenative healing response with regrowth of healthy cilia and mucus-producing cells. CSA Medical has been granted FDA Breakthrough Device Designation and, in January 2026, submitted a Premarket Approval (PMA) application to the FDA supported by positive results from the SPRAY-CB pivotal trial across 20+ US clinical sites, with over 500 procedures completed and zero pneumothoraces reported. The RejuvenAir System received CE Mark approval in the EU in December 2019 and is commercially available in Europe.
The company targets the more than 9 million Americans and 23 million Europeans diagnosed with chronic bronchitis, a large COPD subset underserved by current symptom-management pharmacotherapy. CSA Medical's go-to-market motion centers on interventional pulmonologists at major academic and tertiary medical centers, with the SPRAY-CB clinical trial network (Temple, Cleveland Clinic, Duke, Beth Israel Deaconess, UC Davis, UT Southwestern, etc.) forming the foundation for its post-approval US enterprise sales channel. Revenue model is hardware-based device and consumable sales to hospitals; the device is investigational in the US (pre-revenue) and commercially sold in the EU. The company has raised over $150 million across multiple venture rounds, including a $53 million Series D in September 2024 led by TVM Capital Life Science and Yonjin Ventures. CSA Medical is led by President and CEO Wendelin Maners, with Heather Nigro serving as SVP of Regulatory, Quality and Clinical Affairs.
CSA Medical firmographics
Firmographics- Name
- CSA Medical
- Legal name
- CSA Medical, Inc.
- Website
- https://rejuvenair.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CSA Medical is a US private medical device company developing the RejuvenAir System, a bronchoscopic liquid nitrogen spray cryotherapy platform that targets the underlying cause of chronic bronchitis in COPD patients. It serves interventional pulmonologists and major medical centers, holds FDA Breakthrough Designation, has submitted a PMA in January 2026, and is CE Mark commercial in the EU.
- Ownership category
- akta.pro rank
CSA Medical industry classification
Industry- Product category
- Respiratory Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bronchoscopy & Interventional Pulmonology (HLAKANAJ)
- akta.pro secondary industry
- COPD & Chronic Bronchitis Management (HLAKANAE)
Keywords
Where CSA Medical is headquartered
LocationHeadquarters
- HQ city
- Lutherville Timonium
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CSA Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales - RejuvenAir System: CSA Medical is a medical device company developing the RejuvenAir System for treating chronic bronchitis. The company is currently pre-revenue in the US as the device is investigational. The device received CE Mark approval in the EU in December 2019 and is commercially available there. Upon FDA PMA approval, the company plans to commercialize in the US through interventional pulmonologists at hospitals and medical centers.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
CSA Medical product offering
Product offeringCore offering
CSA Medical develops and manufactures the RejuvenAir System, a cryosurgical medical device that applies metered doses of -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure to treat chronic bronchitis in COPD patients. The Metered CryoSpray (MCS) technology destroys damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cilia and mucus-producing cells. The system is approved in the EU (CE Mark, December 2019) and under FDA Premarket Approval review in the United States.
Product overview
CSA Medical is a medical device company with a single unified product offering: the RejuvenAir System. This system utilizes Metered CryoSpray (MCS) technology to deliver liquid nitrogen cryotherapy bronchoscopically to treat the underlying cause of chronic bronchitis in COPD patients. The RejuvenAir System is designed to destroy damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cells including cilia and normal mucus-producing cells.
Differentiator
Problem solved
Functional benefit
Brands
- RejuvenAir: RejuvenAir System - A breakthrough medical device using Metered CryoSpray therapy for the treatment of chronic bronchitis in COPD patients. The system applies precise thermal dose of extremely cold (-196°C) liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure.
Products and services
- RejuvenAir System A cryosurgical medical device that delivers metered doses of -196°C liquid nitrogen spray (Metered CryoSpray technology) to targeted areas within the lungs through a minimally invasive, outpatient bronchoscopic procedure. The system ablates damaged airway cells while preserving the extracellular matrix, enabling rejuvenative healing in COPD patients with chronic bronchitis. Sold to interventional pulmonology departments at hospitals and academic medical centers.
Quantifiable outcome
- SPRAY-CB pivotal trial met primary endpoint and multiple secondary endpoints with statistical significance
- +4 more outcomes
Companies that use CSA Medical
Customer profileNamed customers9 records
Segments1 record
Ideal customer profiles1 record
CSA Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CSA Medical partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and major.
- Imperial College London (National Heart and Lung Institute)coreResearchers at NHLI, Imperial College London conducted mechanism of action studies demonstrating rejuvenative healing after MCS treatment. Found reduction in abnormal lung epithelium morphology and altered DNA methylation pathways linking tissue regeneration to quality of life improvements. Presented findings at ERS Congress.
- Royal Brompton Hospital, LondoncoreDr. Christopher Orton and Professor Pallav Shah conducted pivotal European feasibility studies and first randomized controlled study. Presented 36-month data showing safety and efficacy. Principal investigators for mechanism of action studies.
- Temple University (Temple Lung Center)coreSPRAY-CB pivotal trial site. Dr. Gerard J. Criner, Chair and Professor of Thoracic Medicine and Surgery, performed the first SPRAY-CB procedure on October 14, 2020.
- UC Davis Medical CentermajorSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology / Pulmonary Care.
- UT Southwestern Medical CentermajorSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology / Pulmonary Care.
- Beth Israel Deaconess Medical CentermajorSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Adnan Majid, Interventional Pulmonology / Pulmonary Care.
- Duke University School of MedicinemajorSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Wahidi, Interventional Pulmonology / Pulmonary Care.
- The Cleveland Clinic FoundationmajorSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Gildea, Interventional Pulmonology / Pulmonary Care.
- Walter Reed National Military Medical CentermajorDr. Robert Browning Jr., Professor of Medicine and Medical Director of Interventional Pulmonology, has presented RejuvenAir technology development and clinical data at medical conferences.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
CSA Medical competitors and assessment
Company assessmentDirect peers
- Pulmonx: Pulmonx markets the Zephyr Endobronchial Valve System, a bronchoscopic device for treating severe emphysema/COPD. It is the most directly comparable commercial-stage interventional pulmonology company, addressing the same patient population with a different bronchoscopic lung volume reduction mechanism.
Emerging players
- Nuvaira: Nuvaira is developing targeted lung denervation (TLD) for COPD, a catheter-based bronchoscopic procedure targeting airway neural hyperactivity. It is an emerging interventional pulmonology player addressing the same COPD population with a different mechanism and represents a future competitor to RejuvenAir.
- Broncus Medical: Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems. Comparable as an emerging player in the bronchoscopic interventional space serving interventional pulmonologists, although its primary focus is lung cancer diagnostics rather than COPD therapy.
Broad incumbents
- Spiration (Olympus): Spiration, acquired by Olympus, developed the Spiration Valve System for emphysema and is part of Olympus's broader interventional pulmonology portfolio. Comparable as a bronchoscopic lung volume reduction modality, but Olympus offers a much wider respiratory/endoscopy product portfolio.
- Medtronic: Medtronic has a significant interventional pulmonology and lung cancer diagnostics franchise, including acquired technologies in bronchoscopy navigation and ablation. Comparable as a broad incumbent with overlapping capabilities in interventional pulmonology, though it does not focus specifically on chronic bronchitis spray cryotherapy.
- Boston Scientific: Boston Scientific acquired BTG/PneumRx (coils for emphysema) and has a broader interventional pulmonary portfolio. It is comparable as a large incumbent player in interventional lung therapies, but its portfolio spans multiple specialties beyond chronic bronchitis.
- Johnson & Johnson (Auris Health): Johnson & Johnson acquired Auris Health (Monarch robotic bronchoscopy platform), positioning itself in the interventional pulmonology space for lung cancer diagnosis and therapy. While focused on robotic bronchoscopy, it represents a large incumbent competing for interventional pulmonology procedure volume and KOL mindshare.
Others
- Intuitive Surgical: Intuitive Surgical is the leader in robotic-assisted surgery including thoracic applications via the da Vinci platform. While not a direct competitor to spray cryotherapy for chronic bronchitis, it competes for interventional pulmonology procedural share and capital budgets at major medical centers.
- Penumbra: Penumbra develops catheter-based technologies primarily for vascular thrombectomy, with emerging presence in respiratory and other specialties. Not a direct competitor, but a relevant catheter-based medical device peer with similar scale and growth trajectory in interventional therapies.
- Steris: Steris provides sterilization, infection prevention, and procedural support products used widely in endoscopy and bronchoscopy suites. Relevant as an adjacent enabling participant whose products support the broader interventional pulmonology procedural ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CSA Medical social profiles
Digital presenceCSA Medical compliance and trust
Trust signalCompliance2 records
CSA Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
CSA Medical leadership team
Management profileNumber of profiles
Profiles3 records
CSA Medical funding detail
Funding detailFunding overview
Funding rounds10 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CSA Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CSA Medical
What does CSA Medical do?
CSA Medical develops and manufactures the RejuvenAir System, a cryosurgical medical device that applies metered doses of -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure to treat chronic bronchitis in COPD patients. The Metered CryoSpray (MCS) technology destroys damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cilia and mucus-producing cells. The system is approved in the EU (CE Mark, December 2019) and under FDA Premarket Approval review in the United States.
Is CSA Medical a public or private company?
CSA Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was CSA Medical founded?
CSA Medical was founded in 1993. It employs 51 to 100 people.
Where is CSA Medical based?
CSA Medical is headquartered in Lutherville Timonium, United States, in the North America region.
How does CSA Medical make money?
One revenue line is on record: medical Device Sales - RejuvenAir System.
Who are CSA Medical's main competitors?
Pulmonx is listed as a direct peer. Emerging players are Nuvaira and Broncus Medical. Broad incumbents are Spiration (Olympus), Medtronic, Boston Scientific and Johnson & Johnson (Auris Health). Others are Intuitive Surgical, Penumbra and Steris.
Does CSA Medical have an API?
No public API is recorded for CSA Medical.
What industry is CSA Medical in?
CSA Medical's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 339113 and its SIC code is 3841.